© 2008 International Society of Nephrology

A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease

D Fouque[1,17], K Kalantar-Zadeh[2,17], J Kopple[2], N Cano[3], P Chauveau[4], L Cuppari[5], H Franch[6], G Guarnieri[7], TA Ikizler[8], G Kaysen[9,10], B Lindholm[11], Z Massy[12,13], W Mitch[14], E Pineda[15], P Stenvinkel[11], A Trevinho-Becerra[15] and C Wanner[16]

[1]Department of Nephrology, Hopital Edouard Herriot, Université Lyon 1, U870 INSERM, Lyon, France; [2]Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center, University of California (UCLA), Torrance, California, USA; [3]CRNH Auvergne, 58 rue Montalembert, Clermont-Ferrand, France; [4]Service de Néphrologie, CHU Bordeaux, Place Amélie Raba-Léon, Bordeaux, France; [5]Division of Nephrology, Federal University of São Paulo, São Paulo, Brazil; [6]Renal Division, Emory University School of Medicine, Atlanta, Georgia, USA; [7]Division of Internal Medicine, Department of Clinical, Morphological and Technological Sciences, University of Trieste, Trieste, Italy; [8]Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee, USA; [9]Departments of Medicine and Biochemistry and Molecular Medicine, University of California (UC) Davis, Davis, California, USA; [10]VANCHCS, Mather, California, USA; [11]Division of Baxter Novum and Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; [12]INSERM ERI-12, Amiens, France; [13]Amiens University Hospital, UPJV, Amiens, France; [14]Nephrology Division, Baylor College of Medicine, Houston, Texas, USA; [15]Faculty of Medicine, Autonomous National University of Mexico, Mexico City, Mexico and [16]Department of Medicine, University Hospital, Wuerzburg, Germany

The recent research findings concerning syndromes of muscle wasting, malnutrition, and inflammation in individuals with chronic kidney disease (CKD) or acute kidney injury (AKI) have led to a need for new terminology. To address this need, the International Society of Renal Nutrition and Metabolism (ISRNM) convened an expert panel to review and develop standard terminologies and definitions related to wasting, cachexia, malnutrition, and inflammation in CKD and AKI. The ISRNM expert panel recommends the term 'protein–energy wasting' for loss of body protein mass and fuel reserves. 'Kidney disease wasting' refers to the occurrence of protein–energy wasting in CKD or AKI regardless of the cause. Cachexia is a severe form of protein–energy wasting that occurs infrequently in kidney disease. Protein–energy wasting is diagnosed if three characteristics are present (low serum levels of albumin, transthyretin, or cholesterol), reduced body mass (low or reduced body or fat mass or weight loss with reduced intake of protein and energy), and reduced muscle mass (muscle wasting or sarcopenia, reduced mid-arm muscle circumference). The kidney disease wasting is divided into two main categories of CKD- and AKI-associated protein–energy wasting. Measures of chronic inflammation or other developing tests can be useful clues for the existence of protein–energy wasting but do not define protein–energy wasting. Clinical staging and potential treatment strategies for protein–energy wasting are to be developed in the future.

Kidney International (2008) **73,** 391–398; doi:10.1038/sj.ki.5002585; published online 19 December 2007

KEYWORDS: malnutrition; inflammation; protein–energy wasting; cachexia; kidney disease wasting; anorexia

Correspondence: *D Fouque, Department of Nephrology, Hopital Edouard Herriot, Lyon Cedex 03, Lyon 69437, France. E-mail: denis.fouque@chu-lyon.fr*

This report is based on the XII International Congress of Renal Nutrition and Metabolism conducted by the International Society of Renal Nutrition and Metabolism (ISRNM), ISRNM Expert Panel, at Meridá, Mexico, from 28 February to 3 March 2006.

[17]These authors contributed equally to this work.

Received 2 March 2007; revised 29 August 2007; accepted 5 September 2007; published online 19 December 2007

There has been an increase of mechanisms causing syndromes of wasting, malnutrition, inflammation, and their interrelationships in individuals with chronic kidney disease (CKD) or acute kidney injury (AKI). Currently, there appears to be some confusion regarding the terms and definitions used for conditions associated with loss of muscle and fat tissue, malnutrition, and inflammation in patients with CKD or AKI. Use of non-uniform and ill-defined terminologies may lead to both conceptual errors and misinterpretation of data. The development of a uniform nomenclature, definition, and classification for the presence of loss of muscle and fat tissues (that is, wasting) or the presence of malnutrition and/or inflammation in individuals with kidney disease could lead to benefits by engendering a more systematic and rational approach to both research and the clinical management of such patients.[1–3] Other groups have addressed the need for more exact definitions and stages of illness in kidney disease, including the Kidney Disease Outcome Quality Initiative (KDOQI)[4] and Kidney Disease Improving Global Outcomes (KDIGO).[5–7]

Owing to the foregoing matters, the International Society of Renal Nutrition and Metabolism (ISRNM) convened an expert panel to re-examine the terms and criteria used for the diagnosis of the wasting syndrome, distinct from malnutrition and inflammation in individuals with CKD or AKI. During the biannual conference of the ISRNM in Meridá, Mexico, from 28 February to 3 March 2006, and the annual meeting of the American Society of Nephrology in San Diego, CA, 16–19 November 2006, the panel met to address these issues of nomenclature. The current position paper is the result of these deliberations and expresses the opinion of the clear majority of the panel.

THE SYNDROMES OF MALNUTRITION, INFLAMMATION, CACHEXIA, AND WASTING

Surveys using classic measures of nutritional status indicate that approximately 18–75% of patients with CKD undergoing maintenance dialysis therapy show evidence of wasting.[1,8,9] These syndromes have been referred to as uremic malnutrition,[10,11] uremic (renal) cachexia,[12–15] protein–energy malnutrition,[16–18] malnutrition–inflammation atherosclerosis syndrome,[19–21] or malnutrition–inflammation complex (or cachexia) syndrome.[9,22] In the last 5 years, it has become apparent that many of the measures indicating the presence of wasting and abnormalities in protein–energy nutritional status can also be induced by inflammatory processes.[23–26] Simply stated, malnutrition refers to abnormalities induced by an inadequate diet, whereas wasting refers to abnormalities that cannot be corrected solely by increasing the diet.[2,3] For example, pure malnutrition can be associated with reduced serum albumin concentrations, but marked reductions are unusual, while the presence of inflammation is frequently associated with a decrease in serum albumin, where marked reductions are common.[27] Inflammation may also be associated with an increase in protein catabolism that is presumably related to the elaboration of catabolic or antianabolic proinflammatory cytokines.[28] Thus, malnutrition refers to the presence of a low-nutrient intake or, at least, an intake that is inadequate for the nutritional needs of the individual. In contrast, an increase in proinflammatory cytokines such as tumor necrosis factor-α and interleukin-6 may cause loss of protein stores and also can induce anorexia with reduced nutrient intake.[29] The difference is that inflammation or other problems associated with loss of kidney function (for example, metabolic acidosis or impaired insulin/insulin-like growth factor-1 signaling pathways) can impair protein anabolism independently of whether adequate nutrition is present.[24]

The relative contributions of malnutrition or inflammation to mortality are obscured because many indicators of malnutrition and inflammation are identical (e.g., low serum albumin and prealbumin concentrations, protein intake, and even body weight-for-height measures, such as body mass index (BMI)).[30] Moreover, loss of muscle and fat stores and inflammation are likely to increase the risk of death from cardiovascular or cerebrovascular disease (possibly by promoting vascular endothelial damage[26,31–33]).

PROTEIN–ENERGY WASTING

Protein–energy wasting (PEW) is the state of decreased body stores of protein and energy fuels (that is, body protein and fat masses). This abnormality is often associated with diminished functional capacity related to metabolic stresses. Protein or energy depletion can result from an inadequate diet (for example, anorexia nervosa), but in kidney disease, in contrast to anorexia nervosa, there are conditions resulting in loss of lean body mass not related to reduced nutrient intake. These include nonspecific inflammatory processes; transient, intercurrent catabolic illnesses;[34] nutrient losses into dialysate;[35–37] acidemia;[38–40] endocrine disorders such as resistance to insulin,[41] growth hormone,[42] and insulin-like growth factor-1;[43] hyperglucagonemia;[44] hyperparathyroidism;[45] and loss of blood into the hemodialyzer, into feces or by blood drawing.[46] It is possible, but not proven, that malnutrition may also predispose to inflammatory states as shown in animal models.[47] Thus, we believe that the most desirable term for describing the syndrome of depletion of protein mass and/or energy fuel supplies is 'protein–energy wasting'. Since protein wasting and energy wasting may occasionally occur separately from each other, the term 'protein wasting' or 'energy wasting' may be used to indicate the isolated occurrence of only one of these phenomena. Potential causes and consequences of PEW are depicted in Figure 1.

CACHEXIA

Recently, the word 'cachexia' has been suggested as a term to denote PEW included in the setting of kidney disease.[12–15,48] Cachexia refers to a very severe form of PEW, often associated with profound physiological, metabolic, psychological, and immunological disorders.[49] 'Cachexia is a complex syndrome that often develops as a serious complication of various chronic diseases.'[50,51] 'Cachexia carries a very poor prognosis and almost no therapies for its treatment are approved, apart from that for acquired immune deficiency syndrome (AIDS)-induced cachexia.'[50,51]

The difference in PEW compared to cachexia is that the latter encompasses only severe forms of metabolic depletion, whereas PEW can refer to mild degrees of depleted protein and energy mass. It would seem to be a contradiction to classify mild protein or energy depletion as cachexia. Modified terms such as 'latent cachexia' neither describe the body mass or composition of an individual nor mechanistically denote metabolic processes and are not recommended,[48] whereas cachexia may be used for severe forms of PEW (Figure 1).

OTHER TERMINOLOGIES

Other terms used to indicate the existence of 'malnutrition' in patients with kidney disease include uremic malnutrition,[10,11] protein–energy malnutrition,[16–18] malnutrition–inflammation atherosclerosis syndrome,[19–21] and malnutrition–inflammation complex syndrome.[9,22] Because 'malnutrition' may indicate both undernutrition and overnutrition,[52,53] there is an additional interpretational problem when it is used to



Figure 1 | Schematic representation of the causes and manifestations of the protein–energy wasting syndrome in kidney disease.

describe the wasting syndrome occurring in acute kidney disease or CKD.[53] Clearly characterizing the entire wasting syndrome as malnutrition will lead to underrecognition of the role of other contributing factors such as hypercatabolism, inflammation, acidemia, or oxidative stress.[3]

Some investigators have suggested classifying the wasting syndrome based on the presence or absence of coexisting inflammation.[20] Oxidative stress may also contribute to kidney disease-related wasting.[54,55] However, we believe that labeling the problems of patients with kidney disease as 'inflammatory wasting' may erroneously imply that the PEW syndrome is due exclusively to inflammation.

KIDNEY DISEASE WASTING

Individuals with CKD or AKI are at increased risk for PEW, and the term, kidney disease wasting (KDW), emphasizes this common association. However, there are many causes of PEW in individuals with kidney disease, and KDW does not provide any insights into the different causes of PEW. In addition, some patients may develop severe PEW before they develop kidney failure.

For example, a new onset maintenance dialysis patient who has been severely depressed psychologically all of his adult life, who has eaten poorly for the last 5 years, and who has chronic PEW can be diagnosed with KDW even though the cause of his PEW is not related to kidney disease. Similarly, a patient with CKD stage 4 and advanced AIDS or vasculitis can be cachectic, but the PEW is not caused by kidney disease. The connotation that many people will infer from the term KDW is that the protein–energy malnutrition is at least partly caused by kidney disease. The same disassociation may be found between patients with AKI and causes of PEW. For example, the causes and medical management of PEW in a young, previously healthy individual who develops pancreatitis, sepsis, and AKI may be quite different from those of an individual 85 years old with chronic congestive heart failure, chronic obstructive pulmonary disease, pneumonia, septicemia, and AKI. For these reasons, the clear majority of the panel members prefer PEW to KDW for most circumstances. The panel believes that the term KDW is not a suitable substitute for PEW but simply implies that PEW is likely to occur in people with CKD or AKI. Figure 1 contains a schematic representation of PEW and its complex interrelationships with several conditions that may lead to or aggravate PEW in kidney disease.

DIAGNOSIS OF PEW

There are several clinical, nutritional, and biochemical parameters that may be indicative of PEW in individuals with kidney disease. The expert panel recommends that four main and established categories be recognized for the diagnosis of PEW: biochemical criteria; low body weight, reduced total body fat, or weight loss; a decrease in muscle mass; and low protein or energy intakes (Table 1). The panel recognizes additional measures of nutrition and inflammation, including some currently under development, which can be regarded as potential clues to the existence of PEW (Table 2).

Among biochemical indicators that can be used for the diagnosis of PEW, serum albumin is known to have strong and consistent outcome-predictability of mortality in epidemiologic studies of dialysis patients.[62–66] Although low serum albumin is often associated with severe clinical disease states, the epidemiological relationship to mortality is based upon the low serum albumin *per se* and poor outcome. It follows

from Table 1 that a low serum albumin concentration is not necessary or sufficient for the diagnosis of PEW, although it is often present in this condition. Serum prealbumin, also known as transthyretin,[67,68] and cholesterol have also been studied as nutritional markers in CKD patients.[67,69–71] The expert panel recommends that at least one biochemical indicator be included when making the clinical diagnosis of PEW (Table 1). The level of serum C-reactive protein or other inflammatory markers, including such circulating proinflammatory cytokines as interleukin-6, may also be persistently increased in PEW,[31,33,72] but these measurements should not be used as part of the criteria for the diagnosis of PEW (Table 2).

Among indicators of body mass, BMI is the most commonly used measure of weight-for-height[73–75] and may be used to assess PEW. However, BMI can be heavily influenced by fat mass or hydration status. Nonetheless, a low BMI is a consistent predictor of poor outcome and high death risk in maintenance dialysis patients.[76,77] The ISRNM panel recommends that a BMI less than 23 $kg\,m^{-2}$ is a marker of PEW. The panel also recognizes that the threshold for this criterion may need further adjustment; especially in some populations, such as those from southeast Asia, a low BMI may not indicate pathology.[78,79] We also note that these suggested values of BMI should not be expanded to recommendations for the general population, because obesity should be avoided. Notably, the World Health Organization recommends a BMI range between 18.5 and 25 $kg\,m^{-2}$ as the normal range for the general population.[80]

Unintentional weight loss or reduction in BMI of any degree should suggest the presence of PEW in individuals with kidney disease. Currently, the expert panel recommends that a loss of 5% of non-edematous weight within 3 months or an unintentional loss of 10% of non-edematous weight over the past 6 months should be considered an indicator of PEW, independently of weight-for-height measures.

The panel considered the use of body fat as a percentage of weight as an additional criterion for wasting, because BMI is strongly, but not solely, influenced by body fat.[81] Moreover, a decrease in body fat in epidemiologic studies has been

Table 1 | Readily utilizable criteria for the clinical diagnosis of PEW in AKI or CKD

Criteria
Serum chemistry
Serum albumin <3.8 g per 100 ml (Bromcresol Green)[a]
Serum prealbumin (transthyretin) <30 mg per 100 ml (for maintenance dialysis patients only; levels may vary according to GFR level for patients with CKD stages 2–5)[a]
Serum cholesterol <100 mg per 100 ml[a]
Body mass
BMI <23[b]
Unintentional weight loss over time: 5% over 3 months or 10% over 6 months
Total body fat percentage $<10\%$
Muscle mass
Muscle wasting: reduced muscle mass 5% over 3 months or 10% over 6 months
Reduced mid-arm muscle circumference area[c] (reduction $>10\%$ in relation to 50th percentile of reference population)
Creatinine appearance[d]
Dietary intake
Unintentional low DPI $<0.80\,g\,kg^{-1}\,day^{-1}$ for at least 2 months[e] for dialysis patients or $<0.6\,g\,kg^{-1}\,day^{-1}$ for patients with CKD stages 2–5
Unintentional low DEI $<25\,kcal\,kg^{-1}\,day^{-1}$ for at least 2 months[e]

AKI, acute kidney injury; BMI, body mass index; CKD, chronic kidney disease; DEI, dietary energy intake; DPI, dietary protein intake; GFR, glomerular filtration rate; nPCR, normalized protein catabolic rate; nPNA, normalized protein nitrogen appearance; PEW, protein–energy wasting.
At least three out of the four listed categories (and at least one test in each of the selected category) must be satisfied for the diagnosis of kidney disease-related PEW. Optimally, each criterion should be documented on at least three occasions, preferably 2–4 weeks apart.
[a]Not valid if low concentrations are due to abnormally great urinary or gastrointestinal protein losses, liver disease, or cholesterol-lowering medicines.
[b]A lower BMI might be desirable for certain Asian populations; weight must be edema-free mass, for example, post-dialysis dry weight. See text for the discussion about the BMI of the healthy population.
[c]Measurement must be performed by a trained anthropometrist.
[d]Creatinine appearance is influenced by both muscle mass and meat intake.
[e]Can be assessed by dietary diaries and interviews, or for protein intake by calculation of normalized protein equivalent of total nitrogen appearance (nPNA or nPCR) as determined by urea kinetic measurements.

Table 2 | Other potential tools (including those still in development) for assessment of PEW in individuals with CKD stages 3–5 or AKI

Appetite, food intake, and energy expenditure
Appetite assessment questionnaires
Population-based dietary assessments: food frequency questionnaires
Measuring energy expenditure by indirect or direct calorimetry
Body mass and composition
Weight-based measures: weight-for-height
Total body nitrogen
Total body potassium
Energy-beam-based methods: DEXA, NIR, BIA, and Vector
Bioimpedance Analysis
Underwater weighing and air displacement weighing
14 kDa fragment of actomyosin
Microarrays
Muscle fiber size
Relative proportions of muscle fiber types
Muscle alkaline soluble protein
CT and/or MRI of muscle mass
Laboratory markers
Serum biochemistry: transferrin, urea, triglyceride, bicarbonate
Hormones: leptin, ghrelin, growth hormones
Inflammatory markers: CRP, IL-6, TNF-α, IL-1, SAA
Peripheral blood cell count: lymphocyte count or percentage
Nutritional scoring systems
SGA and its modifications, including DMS[56,57] and CANUSA version[58]
MIS[59]
Other scoring tools: Wolfson *et al.*,[60] Merkus *et al.*[61]

BIA, bioelectrical impedance analysis; CANUSA, Canada–USA study-based modification of the SGA; CRP, C-reactive protein; CT, computed tomography; DEXA, dual-energy X-ray absorptiometry; DMS, dialysis malnutrition score; HD-PNI, hemodialysis prognostic nutritional index; IGF-1, insulin-like growth factor-1; IL, interleukin (e.g., IL-1 and IL-6); MIS, malnutrition–inflammation score; MRI, magnetic resonance imaging; NIR, near infrared interactance; SAA, serum amyloid A; SGA, subjective global assessment of nutritional status; SUN, serum urea nitrogen; TNF-α, tumor necrosis factor-α.

associated with an increase in the risk of death in maintenance dialysis patients.[82–84] But, the majority of the expert panel members agree that a total body fat below 10% in individuals who are not overtly muscular may be hazardous; there is no consensus on this point and a value suggesting the presence of PEW would be body fat below 10% of weight.[82–84]

A reduced muscle mass appears to be the most valid criterion for the presence of PEW (Table 1).[85,86] A popular term, sarcopenia, has been used to describe the loss of muscle mass that occurs in elderly patients. Hence, sarcopenia, by this definition, should not be applied to the PEW of patients with kidney disease unless this loss of muscle mass occurs in an elderly individual.

It is often difficult to diagnose low muscle mass or muscle loss accurately.[87] Currently, there are no clinically useful, uniform and reproducible measures of lost muscle mass and methods for assessing the presence of accelerated muscle protein catabolism.[88] Some studies have suggested indirect measures of muscle mass, such as serum creatinine, obtained immediately before a hemodialysis treatment in maintenance hemodialysis patients, or the creatinine appearance (net creatinine generation)[89–92] (Table 1). The term 'creatinine appearance' rather than 'creatinine generation' is used because some creatinine is degraded in the intestinal tract[93] and the rate of creatinine degradation increases in patients who have very elevated serum creatinine concentrations. Thus, without isotopic kinetic studies to quantitate the rate of creatinine degradation or synthesis, it is not possible to assess the absolute rate of creatinine generation. We therefore recommend the term creatinine appearance, which can also be estimated by measurement of creatinine in 24 h urine collection and in the collected spent dialysate. The term 'urea nitrogen appearance,' rather than 'urea generation,' has been used for the same reasons.[94]

The accuracy and reproducibility of serum creatinine as an indirect measure of muscle mass is not very precise, especially in dialysis patients receiving different doses of dialysis.[77] Nonetheless, in many diseases, there is clinical and prognostic importance when loss of muscle mass is documented and hence, the panel agrees that it should be included as a clinical criterion for the diagnosis of PEW. Emphasis is placed on assessing the loss of muscle mass because of the limitations of assessing changes in body weight in patients with impaired salt and water regulation, and on the fact that there are many pitfalls in diagnosing the adequacy of the diet.[95,96]

Bioelectrical impedance analysis (BIA) has become a commonly used technique for estimating body water and, by inference, muscle mass[97] (Table 2). The BIA phase angle has been correlated with mortality rate in maintenance hemodialysis (MHD) patients.[98] Vector Bioimpedance Analysis has been reported as a more sensitive and accurate method for estimating the state of hydration in chronic dialysis patients.[99] Multifrequency sum of segments bioimpedance may be more sensitive for estimating muscle mass.[100] The near infrared interactance is a simple method to assess percent body fat via light emission using near infrared spectroscopy on the biceps of the dominant arm and has high correlation with hydrostatic densitometry.[101] Near infrared measurements of body fat have been shown to correlate significantly with other nutritional measures[102,103] and predict survival[84] in maintenance hemodialysis patients.

The panel recognizes that diminished appetite (anorexia) can be associated with PEW and may herald a poor clinical outcome.[29,104] Hence, an unintentional reduction in dietary protein intake less than about 0.80 g per kg body weight per day in maintenance dialysis patients and dietary energy intake less than about 25 kcal per kg body weight can be associated with PEW.[4] It is also recognized that there are pitfalls in identifying a decrease in energy intake.[95,96] We recognize that these criteria are quite conservative, and most maintenance dialysis patients will have dietary protein needs and most CKD and maintenance dialysis patients will have energy requirements that are substantially higher than these values.[4] We also note that the amount of dietary protein needed for patients with stages 3–5 CKD who are not being treated by maintenance dialysis therapy should be considered to be an exception to this rule.[105,106]

In recent years, nutritional scoring systems have been recommended as practical tools for the diagnosis of malnutrition in individuals with kidney disease (Table 2). The KDOQI expert panel for nutrition[4] as well as the European Best Practice Guidelines Wave II have recommended serial assessments by Subjective Global Assessment of Nutrition (SGA) in CKD patients who undergo maintenance dialysis treatment.[56,107] There are additional nutritional scoring systems, some of which are modified versions of the SGA.[56] Currently, there is no consensus about the relationship of these subjective assessments to the diagnosis of PEW. These scoring systems should be considered as potential clinical markers of PEW status (Table 2) but not as definitive diagnostic indicators of this syndrome.

CONCLUSIONS AND FUTURE STEPS

The purpose of our position paper is to advance a unifying and practical terminology for the PEW syndrome of loss of protein mass and energy stores that occurs in many patients with CKD or AKI. There are a large number of disorders that can cause PEW in patients with kidney disease, including the presence of an inadequate diet, the presence of inflammation, oxidative stress, acidemia, nutrient losses into dialysate, altered responses to anabolic hormones, increased levels of unexcreted toxins, and blood loss. It is hoped that a systematically defined nomenclature and diagnostic criteria for PEW in CKD and AKI will help to clarify thinking and communication, enhance the effectiveness of patient care, and promote more incisive research in this field. Many questions about the description, classification, and treatment of KDW need to be addressed: (1) Can nutritional intervention improve the biochemical and clinical disorders related

to PEW (Table 1)? (2) What is the PEW scoring system that most effectively predicts morbidity and/or mortality? (3) Is there a gender impact on appetite, wasting, inflammation, and outcome? (4) If therapeutic interventions are effective at improving indicators of PEW, will clinical outcomes, including survival, also improve? Randomized, well-designed, controlled trials will be required to answer these and similar questions concerning PEW in AKI and CKD.

ACKNOWLEDGMENTS

This work was supported by the International Society of Renal Nutrition and Metabolism (ISRNM).

REFERENCES

1. Kopple JD. McCollum Award Lecture, 1996: protein–energy malnutrition in maintenance dialysis patients. *Am J Clin Nutr* 1997; **65**: 1544–1557.
2. Mitch WE. Malnutrition: a frequent misdiagnosis for hemodialysis patients. *J Clin Invest* 2002; **110**: 437–439.
3. Stenvinkel P, Heimbürger O, Lindholm B. Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. *Nephrol Dial Transplant* 2004; **19**: 2181–2183.
4. National Kidney Foundation I. Kidney Disease–Dialysis Outcome Quality Initiative: K/DOQI Clinical Practice Guidelines for nutrition in chronic renal failure. *Am J Kidney Dis* 2000; **35**: S1–S140.
5. Uhlig K, Macleod A, Craig J *et al.* Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2006; **70**: 2058–2065.
6. Moe S, Drueke T, Cunningham J *et al.* Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2006; **69**: 1945–1953.
7. Levey AS, Eckardt KU, Tsukamoto Y *et al.* Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2005; **67**: 2089–2100.
8. Mehrotra R, Kopple JD. Nutritional management of maintenance dialysis patients: why aren't we doing better? *Annu Rev Nutr* 2001; **21**: 343–379.
9. Kalantar-Zadeh K, Ikizler TA, Block G *et al.* Malnutrition–inflammation complex syndrome in dialysis patients: causes and consequences. *Am J Kidney Dis* 2003; **42**: 864–881.
10. Pupim LB, Ikizler TA. Uremic malnutrition: new insights into an old problem. *Semin Dial* 2003; **16**: 224–232.
11. Pupim LB, Caglar K, Hakim RM *et al.* Uremic malnutrition is a predictor of death independent of inflammatory status. *Kidney Int* 2004; **66**: 2054–2060.
12. Mak RH, Cheung W, Cone RD *et al.* Mechanisms of disease: cytokine and adipokine signaling in uremic cachexia. *Nat Clin Pract Nephrol* 2006; **2**: 527–534.
13. Cheung W, Yu PX, Little BM *et al.* Role of leptin and melanocortin signaling in uremia-associated cachexia. *J Clin Invest* 2005; **115**: 1659–1665.
14. Mak RH, Cheung W. Energy homeostasis and cachexia in chronic kidney disease. *Pediatr Nephrol* 2006; **21**: 1807–1814.
15. Mak RH, Cheung W, Cone RD *et al.* Leptin and inflammation-associated cachexia in chronic kidney disease. *Kidney Int* 2006; **69**: 794–797.
16. Herselman M, Moosa MR, Kotze TJ *et al.* Protein–energy malnutrition as a risk factor for increased morbidity in long-term hemodialysis patients. *J Ren Nutr* 2000; **10**: 7–15.
17. Lindholm B, Heimbürger O, Stenvinkel P. What are the causes of protein–energy malnutrition in chronic renal insufficiency? *Am J Kidney Dis* 2002; **39**: 422–425.
18. Mehrotra R, Kopple J. Causes of protein–energy malnutrition in chronic renal failure. In: Kopple J, Massry S (eds). *Nutritional Management of Renal Disease*, 2nd edn. Lippincott Williams & Wilkins: Philadelphia, 2003.
19. Stenvinkel P, Heimbürger O, Paultre F *et al.* Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. *Kidney Int* 1999; **55**: 1899–1911.
20. Stenvinkel P, Chung SH, Heimbürger O *et al.* Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. *Perit Dial Int* 2001; **21**(Suppl 3): S157–S162.
21. Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome—the heart of the matter. *Nephrol Dial Transplant* 2002; **17**(Suppl 11): 28–31.
22. Castaneda C, Gordon PL, Parker RC *et al.* Resistance training to reduce the malnutrition–inflammation complex syndrome of chronic kidney disease. *Am J Kidney Dis* 2004; **43**: 607–616.
23. Balakrishnan VS, Guo D, Rao M *et al.* Are inflammatory cytokines the 'evil humors' that increase morbidity and cardiovascular mortality in chronic kidney disease? Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. *Semin Dial* 2005; **18**: 441–443.
24. Stenvinkel P. Inflammation in end-stage renal disease—a fire that burns within. *Contrib Nephrol* 2005; **149**: 185–199.
25. Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. *Hemodial Int* 2004; **8**: 118–129.
26. Avesani CM, Carrero JJ, Axelsson J *et al.* Inflammation and wasting in chronic kidney disease: partners in crime. *Kidney Int Suppl* 2006; **70**: S8–S13.
27. Kaysen GA, Dubin JA, Muller HG *et al.* Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. *Kidney Int* 2002; **61**: 2240–2249.
28. Stenvinkel P, Lindholm B, Heimbürger O. Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease. *Semin Dial* 2004; **17**: 505–515.
29. Kalantar-Zadeh K, Block G, McAllister CJ *et al.* Appetite and inflammation, nutrition, anemia and clinical outcome in hemodialysis patients. *Am J Clin Nutr* 2004; **80**: 299–307.
30. Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. *Am J Kidney Dis* 2001; **38**: 1343–1350.
31. Zimmermann J, Herrlinger S, Pruy A *et al.* Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. *Kidney Int* 1999; **55**: 648–658.
32. Qureshi AR, Alvestrand A, Divino-Filho JC *et al.* Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. *J Am Soc Nephrol* 2002; **13**(Suppl 1): S28–S36.
33. Kalantar-Zadeh K, Kopple JD, Humphreys MH *et al.* Comparing outcome predictability of markers of malnutrition–inflammation complex syndrome in haemodialysis patients. *Nephrol Dial Transplant* 2004; **19**: 1507–1519.
34. Grodstein GP, Blumenkrantz MJ, Kopple JD. Nutritional and metabolic response to catabolic stress in uremia. *Am J Clin Nutr* 1980; **33**: 1411–1416.
35. Wolfson M, Jones MR, Kopple JD. Amino acid losses during hemodialysis with infusion of amino acids and glucose. *Kidney Int* 1982; **21**: 500–506.
36. Ikizler TA, Flakoll PJ, Parker RA *et al.* Amino acid and albumin losses during hemodialysis. *Kidney Int* 1994; **46**: 830–837.
37. Chazot C, Shahmir E, Matias B *et al.* Dialytic nutrition: provision of amino acids in dialysate during hemodialysis. *Kidney Int* 1997; **52**: 1663–1670.
38. Bailey JL, Wang X, England BK *et al.* The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin–proteasome pathway. *J Clin Invest* 1996; **97**: 1447–1453.
39. Kalantar-Zadeh K, Mehrotra R, Fouque D *et al.* Metabolic acidosis and malnutrition–inflammation complex syndrome in chronic renal failure. *Semin Dial* 2004; **17**: 445–465.
40. Pickering WP, Price SR, Bircher G *et al.* Nutrition in CAPD: serum bicarbonate and the ubiquitin–proteasome system in muscle. *Kidney Int* 2002; **61**: 1286–1292.
41. Mak RH. Insulin resistance but IGF-I sensitivity in chronic renal failure. *Am J Physiol* 1996; **271**: F114–F119.
42. Moyle GJ, Daar ES, Gertner JM *et al.* Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 2004; **35**: 367–375.
43. Fouque D, Peng SC, Shamir E *et al.* Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients. *Kidney Int* 2000; **57**: 646–654.
44. Sherwin RS, Bastl C, Finkelstein FO *et al.* Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon. *J Clin Invest* 1976; **57**: 722–731.
45. Kopple JD, Cianciaruso B, Massry SG. Does parathyroid hormone cause protein wasting? *Contrib Nephrol* 1980; **20**: 138–148.
46. Kaplan AA, Halley SE, Lapkin RA *et al.* Dialysate protein losses with bleach processed polysulphone dialyzers. *Kidney Int* 1995; **47**: 573–578.

47. Ling PR, Smith RJ, Kie S *et al.* Effects of protein malnutrition on IL-6-mediated signaling in the liver and the systemic acute-phase response in rats. *Am J Physiol Regul Integr Comp Physiol* 2004; **287**: R801–R808.
48. Kalantar-Zadeh K. Recent advances in understanding the malnutrition–inflammation–cachexia syndrome in chronic kidney disease patients: what is next? *Semin Dial* 2005; **18**: 365–369.
49. Martignoni ME, Kunze P, Friess H. Cancer cachexia. *Mol Cancer* 2003; **2**: 36.
50. Springer J, von Haehling S, Anker SD. The need for a standardized definition for cachexia in chronic illness. *Nat Clin Pract Endocrinol Metab* 2006; **2**: 416–417.
51. Springer J, Filippatos G, Akashi YJ *et al.* Prognosis and therapy approaches of cardiac cachexia. *Curr Opin Cardiol* 2006; **21**: 229–233.
52. Mitch WE. Insights into the abnormalities of chronic renal disease attributed to malnutrition. *J Am Soc Nephrol* 2002; **13**(Suppl 1): S22–S27.
53. Mitch WE. Getting beyond cross-sectional studies of abnormal nutritional indexes in dialysis patients. *Am J Clin Nutr* 2003; **77**: 760–761.
54. Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. *J Am Soc Nephrol* 2004; **15**: 538–548.
55. Himmelfarb J, Stenvinkel P, Ikizler TA *et al.* The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. *Kidney Int* 2002; **62**: 1524–1538.
56. Steiber AL, Kalantar-Zadeh K, Secker D *et al.* Subjective Global Assessment in chronic kidney disease: a review. *J Ren Nutr* 2004; **14**: 191–200.
57. Kalantar-Zadeh K, Kleiner M, Dunne E *et al.* A modified quantitative Subjective Global Assessment of nutrition for dialysis patients. *Nephrol Dial Transplant* 1999; **14**: 1732–1738.
58. Canada–USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. *J Am Soc Nephrol* 1996; **7**: 198–207.
59. Kalantar-Zadeh K, Kopple JD, Block G *et al.* A malnutrition–inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. *Am J Kidney Dis* 2001; **38**: 1251–1263.
60. Wolfson M, Strong CJ, Minturn D *et al.* Nutritional status and lymphocyte function in maintenance hemodialysis patients. *Am J Clin Nutr* 1984; **39**: 547–555.
61. Merkus MP, Jager KJ, Dekker FW *et al.* Predictors of poor outcome in chronic dialysis patients: The Netherlands Cooperative Study on the Adequacy of Dialysis. The NECOSAD Study Group. *Am J Kidney Dis* 2000; **35**: 69–79.
62. Iseki K, Kawazoe N, Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients. *Kidney Int* 1993; **44**: 115–119.
63. Kaysen GA, Gambertoglio J, Jiminez I *et al.* Effect of dietary protein intake on albumin homeostasis in nephrotic patients. *Kidney Int* 1986; **29**: 572–577.
64. Kaysen GA. Biological basis of hypoalbuminemia in ESRD. *J Am Soc Nephrol* 1998; **9**: 2368–2376.
65. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N *et al.* Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. *Nephrol Dial Transplant* 2005; **20**: 1880–1888.
66. Beddhu S, Kaysen GA, Yan G *et al.* Association of serum albumin and atherosclerosis in chronic hemodialysis patients. *Am J Kidney Dis* 2002; **40**: 721–727.
67. Kopple JD, Mehrotra R, Suppasyndh O *et al.* Observations with regard to the National Kidney Foundation K/DOQI clinical practice guidelines concerning serum transthyretin in chronic renal failure. *Clin Chem Lab Med* 2002; **40**: 1308–1312.
68. Cano NJ. Metabolism and clinical interest of serum transthyretin (prealbumin) in dialysis patients. *Clin Chem Lab Med* 2002; **40**: 1313–1319.
69. Gordon JN, Green SR, Goggin PM. Cancer cachexia. *QJM* 2005; **98**: 779–788.
70. Chertow GM, Ackert K, Lew NL *et al.* Prealbumin is as important as albumin in the nutritional assessment of hemodialysis patients. *Kidney Int* 2000; **58**: 2512–2517.
71. Kilpatrick RD, McAllister CJ, Kovesdy CP *et al.* Association between serum lipids and survival in hemodialysis patients and impact of race. *J Am Soc Nephrol* 2007; **18**: 293–303.
72. Bologa RM, Levine DM, Parker TS *et al.* Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. *Am J Kidney Dis* 1998; **32**: 107–114.
73. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD *et al.* Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. *Am J Kidney Dis* 2005; **46**: 489–500.
74. Kopple JD, Zhu X, Lew NL *et al.* Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. *Kidney Int* 1999; **56**: 1136–1148.
75. Culp K, Flanigan M, Dudley J *et al.* Using the Quetelet body mass index as a mortality indicator for patients starting renal replacement therapy. *Anna J* 1998; **25**: 321–330; discussion 331–332.
76. Salahudeen AK. Obesity and survival on dialysis. *Am J Kidney Dis* 2003; **41**: 925–932.
77. Kalantar-Zadeh K, Abbott KC, Salahudeen AK *et al.* Survival advantages of obesity in dialysis patients. *Am J Clin Nutr* 2005; **81**: 543–554.
78. Stevens J, Nowicki EM. Body mass index and mortality in Asian populations: implications for obesity cut-points. *Nutr Rev* 2003; **61**: 104–107.
79. Wong JS, Port FK, Hulbert-Shearon TE *et al.* Survival advantage in Asian American end-stage renal disease patients. *Kidney Int* 1999; **55**: 2515–2523.
80. Joint WHO/FAO Expert Consultation on Diet Nutrition and the Prevention of Chronic Diseases. *Diet, Nutrition and the Prevention of Chronic Diseases: Report of a Joint WHO/FAO Expert Consultation*. World Health Organization: Geneva, Switzerland, 2003.
81. Kalantar-Zadeh K. Causes and consequences of the reverse epidemiology of body mass index in dialysis patients. *J Ren Nutr* 2005; **15**: 142–147.
82. Kakiya R, Shoji T, Tsujimoto Y *et al.* Body fat mass and lean mass as predictors of survival in hemodialysis patients. *Kidney Int* 2006; **70**: 549–556.
83. Fujino Y, Ishimura E, Okuno S *et al.* Annual fat mass change is a significant predictor of mortality in female hemodialysis patients. *Biomed Pharmacother* 2006; **60**: 253–257.
84. Kalantar-Zadeh K, Kuwae N, Wu DY *et al.* Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. *Am J Clin Nutr* 2006; **83**: 202–210.
85. Axelsson J, Qureshi AR, Divino-Filho JC *et al.* Are insulin-like growth factor and its binding proteins 1 and 3 clinically useful as markers of malnutrition, sarcopenia and inflammation in end-stage renal disease? *Eur J Clin Nutr* 2006; **60**: 718–726.
86. Kaysen GA. Diabetes, a cause of progressive sarcopenia in dialysis patients? *Kidney Int* 2005; **68**: 2396–2397.
87. Mak RH, Rotwein P. Myostatin and insulin-like growth factors in uremic sarcopenia: the yin and yang in muscle mass regulation. *Kidney Int* 2006; **70**: 410–412.
88. Workeneh BT, Rondon-Berrios H, Zhang L *et al.* Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions. *J Am Soc Nephrol* 2006; **17**: 3233–3239.
89. Canaud B, Garred LJ, Argiles A *et al.* Creatinine kinetic modelling: a simple and reliable tool for the assessment of protein nutritional status in haemodialysis patients. *Nephrol Dial Transplant* 1995; **10**: 1405–1410.
90. Perez RA, Blake PG, Spanner E *et al.* High creatinine excretion ratio predicts a good outcome in peritoneal dialysis patients. *Am J Kidney Dis* 2000; **36**: 362–367.
91. Bhatla B, Moore H, Emerson P *et al.* Lean body mass estimation by creatinine kinetics, bioimpedance, and dual energy x-ray absorptiometry in patients on continuous ambulatory peritoneal dialysis. *ASAIO J* 1995; **41**: M442–M446.
92. Keshaviah PR, Nolph KD, Moore HL *et al.* Lean body mass estimation by creatinine kinetics. *J Am Soc Nephrol* 1994; **4**: 1475–1485.
93. Mitch WE, Collier VU, Walser M. Creatinine metabolism in chronic renal failure. *Clin Sci (Lond)* 1980; **58**: 327–335.
94. Kopple JD, Gao XL, Qing DP. Dietary protein, urea nitrogen appearance and total nitrogen appearance in chronic renal failure and CAPD patients. *Kidney Int* 1997; **52**: 486–494.
95. Avesani CM, Kamimura MA, Draibe SA *et al.* Is energy intake underestimated in nondialyzed chronic kidney disease patients? *J Ren Nutr* 2005; **15**: 159–165.
96. Kloppenburg WD, de Jong PE, Huisman RM. The contradiction of stable body mass despite low reported dietary energy intake in chronic haemodialysis patients. *Nephrol Dial Transplant* 2002; **17**: 1628–1633.
97. Arkouche W, Fouque D, Pachiaudi C *et al.* Total body water and body composition in chronic peritoneal dialysis patients. *J Am Soc Nephrol* 1997; **8**: 1906–1914.

98. Johansen KL, Kaysen GA, Young BS *et al.* Longitudinal study of nutritional status, body composition, and physical function in hemodialysis patients. *Am J Clin Nutr* 2003; **77**: 842–846.
99. Pillon L, Piccoli A, Lowrie EG *et al.* Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis. *Kidney Int* 2004; **66**: 1266–1271.
100. Kaysen GA, Zhu F, Sarkar S *et al.* Estimation of total-body and limb muscle mass in hemodialysis patients by using multifrequency bioimpedance spectroscopy. *Am J Clin Nutr* 2005; **82**: 988–995.
101. Conway JM, Norris KH, Bodwell CE. A new approach for the estimation of body composition: infrared interactance. *Am J Clin Nutr* 1984; **40**: 1123–1130.
102. Kalantar-Zadeh K, Block G, Kelly MP *et al.* Near infra-red interactance for longitudinal assessment of nutrition in dialysis patients. *J Ren Nutr* 2001; **11**: 23–31.
103. Kalantar-Zadeh K, Dunne E, Nixon K *et al.* Near infra-red interactance for nutritional assessment of dialysis patients. *Nephrol Dial Transplant* 1999; **14**: 169–175.
104. Aguilera A, Codoceo R, Bajo MA *et al.* Eating behavior disorders in uremia: a question of balance in appetite regulation. *Semin Dial* 2004; **17**: 44–52.
105. Klahr S, Levey AS, Beck GJ *et al.* The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med* 1994; **330**: 877–884.
106. Fouque D, Aparicio M. Eleven reasons to control the protein intake of patients with chronic kidney disease. *Nat Clin Pract Nephrol* 2007; **3**: 383–392.
107. Fouque D, Vennegoor M, ter Wee P *et al.* EPBG guideline on nutrition. *Nephrol Dial Transplant* 2007; **22**(Suppl 2): ii45–ii87.